UCB SA (OTCMKTS:UCBJF – Get Free Report) shares reached a new 52-week high on Thursday . The stock traded as high as $152.50 and last traded at $152.50, with a volume of 0 shares traded. The stock had previously closed at $152.50.
UCB Stock Performance
The firm has a fifty day simple moving average of $134.82 and a 200 day simple moving average of $119.87.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
See Also
- Five stocks we like better than UCB
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Why Call Options Volume for These 2 Stocks Spiked Together
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- MarketBeat Week in Review – 7/22 – 7/26
- The 3 Best Fintech Stocks to Buy Now
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
